Guenther Reiter - Epigenomics AG Insider

Epigenomics AG -- USA Stock  

USD 4.98  0.55  12.42%

Member of the Supervisory Board

Prof. Dr. Guenther Reiter is Vice Chairman of the Supervisory Board at Epigenomics AG since November 5, 2014. He was Member of the Supervisory Board since June 28, 2005. He held several managing positions such as Manager Business Administration and Controlling at Trumpf GmbH Co. in Ditzingen and at last as Executive Member of the Hofkammer of Wuerttemberg. As a Dean and Prodean, Prof. Reiter was actively involved in the development of the European School of Business in Reutlingen as Professor. Furthermore, Prof. Dr. Reiter is Member of the Supervisory Board Deltoton GmbH. He graduated from Universitaet Tuebingen in Mathematics and in Business Economics.
Age: 62  Executive Since 2014      
49 30 243 450

Management Efficiency

The company has return on total asset (ROA) of (44.29) % which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (122.69) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.

Similar Executives

Found 2 records


Nancy PaxtonApple Inc
Jonathan IveApple Inc

Entity Summary

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics AG is traded on OTC Market in USA.Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Geneststrasse 5 and employs 43 people.

Did you try this?

Run Chance of Distress Now

Chance of Distress

Get analysis of equity chance of financial distress in the next 2 years
Hide  View All  NextLaunch Chance of Distress

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Epigenomics AG to your portfolio

Top Management

Epigenomics AG Leadership Team
Antje Zeise, Executive
Guenther Reiter, Executive
Gregory Hamilton, CEO, MBA
Ann Kessler, Executive
Heino Prondzynski, Chairman
Helge Lubenow, Executive, Ph.D
Thomas Taapken, CEO
Annett Dietrich, Executive
Noel Doheny, CEO
Uwe Staub, COO, Ph.D
Albert Weber, SVP
Nicola HennebergBusse, President
Jorge Garces, President, MBA
Nicholas Potter, Director
Peter Vogt, Executive

Stock Performance

Epigenomics AG Performance Indicators